[go: up one dir, main page]

MY111055A - Pharmaceutical composition and process for the preparation thereof - Google Patents

Pharmaceutical composition and process for the preparation thereof

Info

Publication number
MY111055A
MY111055A MYPI92002341A MYPI19922341A MY111055A MY 111055 A MY111055 A MY 111055A MY PI92002341 A MYPI92002341 A MY PI92002341A MY PI19922341 A MYPI19922341 A MY PI19922341A MY 111055 A MY111055 A MY 111055A
Authority
MY
Malaysia
Prior art keywords
preparation
pharmaceutical composition
propinylamine
phenyl
methyl
Prior art date
Application number
MYPI92002341A
Inventor
Z Szabo Anna
Jozsef Gaal Dr
Kalman Magyar Dr
Istvan Hermecz Dr
Jozsef Lengyel Dr
Katalin Marmarosi Nee Kellner Mrs
Istvan Sziraki Dr
Istvan Szatmari Dr
Zoltan Torok Dr
Peter Kormoczy Dr
Original Assignee
Chinoin Gyogyzer Et Vegyeszeti Termekek Gyara Rt
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chinoin Gyogyzer Et Vegyeszeti Termekek Gyara Rt filed Critical Chinoin Gyogyzer Et Vegyeszeti Termekek Gyara Rt
Publication of MY111055A publication Critical patent/MY111055A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Psychiatry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

THE INVENTION RELATES TO TWO PHASE PHARMACEUTICAL COMPOSITIONS COMPRISING AS ACTIVE INGREDIENT A MONOAMINE OXIDASE INHIBITOR AND AN UPTAKE INHIBITOR TOGETHER WITH USUAL PHRMACEUTICAL AUXILIARIES. THE COMPOSITION CAN BE USED FOR THE TREATMENT OF NEURADEGENERATIVE DISEASES. AS ACTIVE INGREDIENT OPTIONALLY N - (1-PHENYL - ISOPROPYL) - N - METHYL - PROPINYLAMINE OR N-(4-FLUORO-PHENYL)-ISOPROP-1-YLN-METHYL-PROPINYLAMINE OR THEIR SALTS, OPTICALLY ACTIVE ISOMERS OR METABOLITES ARE USED BOTH AS MONOAMINE OXIDASE INHIBITOR AND AS UPTAKE INHIBITOR.
MYPI92002341A 1991-12-20 1992-12-18 Pharmaceutical composition and process for the preparation thereof MY111055A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
HU914060A HUT63579A (en) 1991-12-20 1991-12-20 Process for producing double-phase pharmaceutical compositions suitable for treating diseases occurring during neurodegenerative processes

Publications (1)

Publication Number Publication Date
MY111055A true MY111055A (en) 1999-08-30

Family

ID=10966728

Family Applications (1)

Application Number Title Priority Date Filing Date
MYPI92002341A MY111055A (en) 1991-12-20 1992-12-18 Pharmaceutical composition and process for the preparation thereof

Country Status (27)

Country Link
US (1) US5589513A (en)
EP (1) EP0617615A1 (en)
JP (1) JPH07502730A (en)
KR (1) KR940703655A (en)
AU (1) AU677170B2 (en)
BG (1) BG98827A (en)
BR (1) BR9206950A (en)
CA (1) CA2125776A1 (en)
CZ (1) CZ147494A3 (en)
EC (1) ECSP930933A (en)
EE (1) EE03015B1 (en)
FI (1) FI942932A7 (en)
HU (2) HUT63579A (en)
IL (1) IL104150A (en)
LT (1) LT3119B (en)
LV (1) LV10386B (en)
MY (1) MY111055A (en)
NO (1) NO942303D0 (en)
NZ (1) NZ246384A (en)
PH (1) PH31073A (en)
PL (1) PL172048B1 (en)
RO (1) RO115785B1 (en)
RU (1) RU2125448C1 (en)
SI (1) SI9200404A (en)
SK (1) SK74494A3 (en)
WO (1) WO1993012775A1 (en)
ZA (1) ZA929883B (en)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5844003A (en) * 1991-04-04 1998-12-01 Innovations Foundation Use of deprenyl compounds to maintain, prevent loss, or recover nerve cell function
US5817336A (en) * 1993-04-02 1998-10-06 Orion-Yhtyma Oy Composition containing selegiline
DE4432610C1 (en) * 1994-09-13 1996-02-01 Knoll Ag Process for the preparation of selegiline hydrochloride
CA2212412A1 (en) 1995-02-10 1996-08-15 The University Of Toronto Innovations Foundation Deprenyl compounds for treatment of glaucoma
JP4499208B2 (en) * 1998-10-29 2010-07-07 株式会社フジモト・コーポレーション Novel optically active aminopentane derivatives
US7374779B2 (en) * 1999-02-26 2008-05-20 Lipocine, Inc. Pharmaceutical formulations and systems for improved absorption and multistage release of active agents
HUP9902482A2 (en) * 1999-07-22 2002-04-29 Chinoin Gyógyszer és Vegyészeti Termékek Gyára Rt. Use of p-fluoro-selegiline for producing neuroprotective pharmaceutical compositions
RU2194983C2 (en) * 2000-06-30 2002-12-20 Научно-исследовательский институт военной медицины Method for evaluating blood serum neurotoxicity in patients suffering from hepatic diseases
EP2053033A1 (en) * 2007-10-26 2009-04-29 Bayer Schering Pharma AG Compounds for use in imaging, diagnosing and/or treatment of diseases of the central nervous system or of tumors
US11304960B2 (en) 2009-01-08 2022-04-19 Chandrashekar Giliyar Steroidal compositions
DE102009045056A1 (en) * 2009-09-28 2011-03-31 Henkel Ag & Co. Kgaa Spotting preparations
US20180153904A1 (en) 2010-11-30 2018-06-07 Lipocine Inc. High-strength testosterone undecanoate compositions
US9034858B2 (en) 2010-11-30 2015-05-19 Lipocine Inc. High-strength testosterone undecanoate compositions
US9358241B2 (en) 2010-11-30 2016-06-07 Lipocine Inc. High-strength testosterone undecanoate compositions
US20120148675A1 (en) 2010-12-10 2012-06-14 Basawaraj Chickmath Testosterone undecanoate compositions
US20170246187A1 (en) 2014-08-28 2017-08-31 Lipocine Inc. (17-ß)-3-OXOANDROST-4-EN-17-YL TRIDECANOATE COMPOSITIONS AND METHODS OF THEIR PREPARATION AND USE
US9498485B2 (en) 2014-08-28 2016-11-22 Lipocine Inc. Bioavailable solid state (17-β)-hydroxy-4-androsten-3-one esters
US20160361322A1 (en) 2015-06-15 2016-12-15 Lipocine Inc. Composition and method for oral delivery of androgen prodrugs
JP2020503269A (en) 2016-11-28 2020-01-30 リポカイン インコーポレーテッド Oral testosterone undecanoate therapy
CA3107214A1 (en) 2018-07-20 2020-01-23 Lipocine Inc. Liver disease

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1227447B (en) * 1962-03-30 1966-10-27 Chinoin Gyogyszer Es Vegyeszet Process for the preparation of phenylisopropylamines
HU193662B (en) * 1983-12-20 1987-11-30 Chinoin Gyogyszer Es Vegyeszet Process for producing synergetic pharmaceutical composition of antidepressive aktivity
HU207282B (en) * 1984-05-31 1993-03-29 Chinoin Gyogyszer Es Vegyeszet Process for producing phenyl-alkyl-amine derivatives and pharmaceutical compositions containing them
DE3764144D1 (en) * 1986-04-16 1990-09-13 Asta Pharma Ag SYNERGISTIC COMBINATION OF AMANTADINE AND SELEGILINE.
HU207280B (en) * 1986-09-25 1993-03-29 Chinoin Gyogyszer Es Vegyeszet Process for producing new phenyl-alkyl-amines and pharmaceutical compositions containing them
HU197510B (en) * 1986-12-19 1989-04-28 Chinoin Gyogyszer Es Vegyeszet Process for producing pharmaceutical composition containing phenyl-alkyl-amine derivatives, against motion-sick
US4861800A (en) * 1987-08-18 1989-08-29 Buyske Donald A Method for administering the drug deprenyl so as to minimize the danger of side effects
GB8807504D0 (en) * 1988-03-29 1988-05-05 Sandoz Ltd Improvements in/relating to organic compounds
HU208484B (en) * 1988-08-17 1993-11-29 Chinoin Gyogyszer Es Vegyeszet Process for producing pharmaceutical composition containing acid additional salt of selegilin as active component for treating schisofrenia
CA2037178A1 (en) * 1990-02-28 1991-08-29 Albert Walter Brzeczko Deprenyl/l-dopa/carbidopa pharmaceutical composition
GB9011767D0 (en) * 1990-05-25 1990-07-18 Britannia Pharmaceuticals Ltd Pharmaceutical compositions
US5169868A (en) * 1991-03-01 1992-12-08 University Of Saskatchewan Aliphatic propargylamines as specific mao-b inhibitors
US5444095A (en) * 1991-04-04 1995-08-22 University Of Toronto, Innovations Foundation Use of deprenyl to rescue damaged nerve cells
HU209605B (en) * 1991-04-15 1994-09-28 Chinoin Gyogyszer Es Vegyeszet Process for production of wather-free transdermal preparation
US5326770A (en) * 1992-07-17 1994-07-05 The Du Pont Merck Pharmaceutical Company Monoamine oxidase-B (MAO-B) inhibitory 5-substituted 2,4-thiazolidinediones useful in treating memory disorders of mammals

Also Published As

Publication number Publication date
AU3265293A (en) 1993-07-28
CZ147494A3 (en) 1995-01-18
LV10386A (en) 1995-02-20
US5589513A (en) 1996-12-31
KR940703655A (en) 1994-12-12
LTIP249A (en) 1994-07-15
HU211478A9 (en) 1995-11-28
WO1993012775A1 (en) 1993-07-08
SI9200404A (en) 1993-06-30
LV10386B (en) 1995-12-20
IL104150A (en) 1997-11-20
ZA929883B (en) 1994-05-16
EP0617615A1 (en) 1994-10-05
NZ246384A (en) 1996-02-27
ECSP930933A (en) 1994-04-20
NO942303L (en) 1994-08-17
BR9206950A (en) 1995-11-28
RO115785B1 (en) 2000-06-30
PL172048B1 (en) 1997-07-31
AU677170B2 (en) 1997-04-17
PH31073A (en) 1998-02-05
CA2125776A1 (en) 1993-07-08
FI942932A0 (en) 1994-06-17
HUT63579A (en) 1993-09-28
HU914060D0 (en) 1992-03-30
EE03015B1 (en) 1997-08-15
RU2125448C1 (en) 1999-01-27
FI942932L (en) 1994-06-17
BG98827A (en) 1995-06-30
FI942932A7 (en) 1994-06-17
JPH07502730A (en) 1995-03-23
SK74494A3 (en) 1995-01-12
LT3119B (en) 1994-12-27
NO942303D0 (en) 1994-06-17

Similar Documents

Publication Publication Date Title
MY111055A (en) Pharmaceutical composition and process for the preparation thereof
NZ240230A (en) Mercaptoacetylamide derivatives; preparation, use and pharmaceutical compositions thereof
EA200200806A1 (en) PREVENTION OF LOSS AND RESTORATION OF BONE MASS BY CERTAIN AGENTISTS PROSTAGLANDINA
GEP20033131B (en) Azabicycloalkanes as CCR5 Modulators, Pharmaceutical Compositions Containing the Same and Their Use for Treatment and Prevention of Diseases Caused by CCR5 Activity
MX9206305A (en) SUBSTITUTE BIPHENYLPYRIDONES, PROCEDURE FOR THEIR OBTAINMENT AND DRUG CONTAINING THEM.
YU56995A (en) ONLY DERIVED INDOLA
IL108382A0 (en) Amino acid derivatives, their preparation and pharmaceutical compositions containing them
EA200201271A1 (en) INHIBITORS 11-BETA-HYDROXYSTEROID DEGYDROGENASE TYPE 1
YU49094B (en) Process for obtaining synenergetic therapeutic composition
TR27835A (en) Substituted azadioxacycloalkenes.
NO883229D0 (en) NEW BENZIMIDAZOLD DERIVATIVES, PROCEDURES FOR THEIR PREPARATION AND PHARMACEUTICAL PREPARATION CONTAINING SUCH DERIVATIVES.
BR9908545A (en) Piperidine derivative, process for preparing it, compound, process for preparing it, and pharmaceutical composition
EA199800357A1 (en) PHARMACEUTICAL ANGIOSTATIC DIPEPTIDE COMPOSITIONS AND METHODS OF THEIR APPLICATION
UA26403A (en) POHIDHI N-ZAMISCHEHOHO 4 FEHIL-4-PIPERYDYHKARBOKSAMIDU FARMATSEVTYCHHO PRYYHYATHI AND THEIR SALTS, showing AHESTEZUVALHU AHALHEZUVALHU AND PERFORMANCE, AND METHOD OF ODERZHAHHYA FARMATSEVTYCHHA COMPOSITION
NO890259D0 (en) PROCEDURE FOR THE PREPARATION OF THERAPEUTIC ACTIVE ETHYLPHENOXYACETAMIDES.
ATE103812T1 (en) COMPOSITION FOR THE TREATMENT OF ISCHEMIC DISORDERS IN ORGANS.
DK442287D0 (en) PHARMACEUTICAL PREPARATION CONTAINING L-3,4-DIHYDROXYPHENYLALANINE (L-DOPA) AS ACTIVE INGREDIENT AND PROCEDURE FOR THE PREPARATION OF SUCH PREPARATION
AR019496A1 (en) AZALIDAS OF 13 MEMBERS, PHARMACEUTICAL COMPOSITIONS, USE IN THE PREPARATION OF MEDICINES AND PREPARATION OF THE SAME
TR199700878T1 (en) Pharmacological compositions containing inhibitors of monamine oxidase B.
RU94044534A (en) Thiazole amino derivatives, processes for preparation thereof and pharmaceutical compositions containing said derivatives
IT1170214B (en) PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF PERIPHERAL ARTERIOPATHIES
BR9813319A (en) Compound, pharmaceutical composition for treating bacterial infections, and processes for treating bacterial infections and for preparing a compound
NO972623D0 (en) Formula mixture comprising lamotrigine
BR9814498A (en) Process for the treatment of obesity in a human requiring such treatment, compound, use of the same, product, and pharmaceutical composition
BG60101B2 (en) METHOD FOR THE PREPARATION OF 4-FLUORO-2-(((4-METHOXY-2- PYRIDINYL)METHYL)THIONYL)-1H-BENZIMIDAZOLE